Scilligence

Scilligence, founded in 2010 and headquartered in the United States, is a prominent provider of cross-platform, mobile cheminformatics and bioinformatics software solutions. Its products have gained traction across a broad spectrum of sectors including pharmaceutical, biotech, and chemical industries, as well as academic and governmental organizations.

The company’s platform is set apart by its robust integration capabilities, enabling seamless internal and external collaborations. It is agnostic of devices and browsers, eliminating the need for Java dependency and offering excellent support for HELM (Hierarchical Editing Language for Macromolecules) notation. This flexibility allows for bespoke configurations, catering to the specific needs of any organization. Additionally, Scilligence offers a cost-effective solution in terms of deployment and maintenance.

With a focus on data analytics and ideation, Scilligence drives innovation in knowledge management and supports R&D through their comprehensive suite of products such as ELN, RegMol, and others. This makes it an attractive consideration for investors looking to back a versatile and well-integrated platform in the life sciences domain.